Expanding possibilities

Dear Friends,

For decades, LLS has served as a “change enthusiast,” playing a role in expanding possibilities for nearly every blood cancer patient. Our mission remains unchanged: Cure leukemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families. More than ever, we are committed to leveling the playing field in blood cancer research and care and addressing the needs of previously underserved populations to ensure a future of expanded hope for all members of our community.

Among our many 2021 achievements, we:

• ...initiated first-of-its-kind research on COVID-19 vaccine efficacy— using data submitted from patients serving as “citizen scientists”—to facilitate vaccine decision-making
• ...promoted a treatment modality that barely existed four years ago and is now creating long remissions in patients on the brink of death
• ...increased financial assistance for patients and families by 70% over last year
• ...enhanced efforts to expand equitable access to care— including clinical trials—for all blood cancer patients, making inroads in communities that have been traditionally overlooked
• ...launched a new program to fund health services research, to ensure enhanced access to blood cancer care and services
• ...advanced the design of a landmark global master trial that promises to revolutionize pediatric standard of care for acute leukemia
• ...set records in fundraising despite global pandemic challenges, allowing for reinvestment into ongoing research and patient programs

Of course, for us, the ultimate expansion of possibility will be a world where blood cancer is no longer a death sentence and can be cured. On behalf of the 1.3 million Americans living with—or in remission from—blood cancer, we will not stop until mission impossible turns into mission possible. With your help we will get there.